These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37963313)

  • 1. Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial.
    Nicolle R; Bachet JB; Harlé A; Iovanna J; Hammel P; Rebours V; Turpin A; Ben Abdelghani M; Wei A; Mitry E; Lopez A; Biagi J; François E; Artru P; Lambert A; Renouf DJ; Monard L; Mauduit M; Dusetti N; Conroy T; Cros J
    J Clin Oncol; 2024 Mar; 42(9):1067-1076. PubMed ID: 37963313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma.
    Fraunhoffer N; Hammel P; Conroy T; Nicolle R; Bachet JB; Harlé A; Rebours V; Turpin A; Ben Abdelghani M; Mitry E; Biagi J; Chanez B; Bigonnet M; Lopez A; Evesque L; Lecomte T; Assenat E; Bouché O; Renouf DJ; Lambert A; Monard L; Mauduit M; Cros J; Iovanna J; Dusetti N
    Ann Oncol; 2024 Sep; 35(9):780-791. PubMed ID: 38906254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma.
    Nicolle R; Gayet O; Duconseil P; Vanbrugghe C; Roques J; Bigonnet M; Blum Y; Elarouci N; Armenoult L; Ayadi M; de Reyniès A; Puleo F; Augustin J; Emile JF; Svrcek M; Arsenijevic T; Hammel P; Giovannini M; Grandval P; Dahan L; Moutardier V; Gilabert M; Van Laethem JL; Bachet JB; Cros J; Iovanna J; Dusetti NJ
    Ann Oncol; 2021 Feb; 32(2):250-260. PubMed ID: 33188873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
    Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial.
    Bouchart C; Navez J; Borbath I; Geboes K; Vandamme T; Closset J; Moretti L; Demetter P; Paesmans M; Van Laethem JL
    BMC Cancer; 2023 Sep; 23(1):891. PubMed ID: 37735634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
    Neoptolemos JP; Stocken DD; Bassi C; Ghaneh P; Cunningham D; Goldstein D; Padbury R; Moore MJ; Gallinger S; Mariette C; Wente MN; Izbicki JR; Friess H; Lerch MM; Dervenis C; Oláh A; Butturini G; Doi R; Lind PA; Smith D; Valle JW; Palmer DH; Buckels JA; Thompson J; McKay CJ; Rawcliffe CL; Büchler MW;
    JAMA; 2010 Sep; 304(10):1073-81. PubMed ID: 20823433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
    Conroy T; Castan F; Lopez A; Turpin A; Ben Abdelghani M; Wei AC; Mitry E; Biagi JJ; Evesque L; Artru P; Lecomte T; Assenat E; Bauguion L; Ychou M; Bouché O; Monard L; Lambert A; Hammel P;
    JAMA Oncol; 2022 Nov; 8(11):1571-1578. PubMed ID: 36048453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group.
    Seufferlein T; Uhl W; Kornmann M; Algül H; Friess H; König A; Ghadimi M; Gallmeier E; Bartsch DK; Lutz MP; Metzger R; Wille K; Gerdes B; Schimanski CC; Graupe F; Kunzmann V; Klein I; Geissler M; Staib L; Waldschmidt D; Bruns C; Wittel U; Fichtner-Feigl S; Daum S; Hinke A; Blome L; Tannapfel A; Kleger A; Berger AW; Kestler AMR; Schuhbaur JS; Perkhofer L; Tempero M; Reinacher-Schick AC; Ettrich TJ
    Ann Oncol; 2023 Jan; 34(1):91-100. PubMed ID: 36209981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial.
    van Dam JL; Verkolf EMM; Dekker EN; Bonsing BA; Bratlie SO; Brosens LAA; Busch OR; van Driel LMJW; van Eijck CHJ; Feshtali S; Ghorbani P; de Groot DJA; de Groot JWB; Haberkorn BCM; de Hingh IH; van der Holt B; Karsten TM; van der Kolk MB; Labori KJ; Liem MSL; Loosveld OJL; Molenaar IQ; Polée MB; van Santvoort HC; de Vos-Geelen J; Wumkes ML; van Tienhoven G; Homs MYV; Besselink MG; Wilmink JW; Groot Koerkamp B;
    BMC Cancer; 2023 Aug; 23(1):728. PubMed ID: 37550634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study.
    De La Fouchardière C; Malka D; Cropet C; Chabaud S; Raimbourg J; Botsen D; Launay S; Evesque L; Vienot A; Perrier H; Jary M; Rinaldi Y; Coutzac C; Bachet JB; Neuzillet C; Williet N; Desgrippes R; Grainville T; Aparicio T; Peytier A; Lecomte T; Roth GS; Thirot-Bidault A; Lachaux N; Bouché O; Ghiringhelli F
    J Clin Oncol; 2024 Mar; 42(9):1055-1066. PubMed ID: 38232341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
    Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
    BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
    Ghaneh P; Palmer D; Cicconi S; Jackson R; Halloran CM; Rawcliffe C; Sripadam R; Mukherjee S; Soonawalla Z; Wadsley J; Al-Mukhtar A; Dickson E; Graham J; Jiao L; Wasan HS; Tait IS; Prachalias A; Ross P; Valle JW; O'Reilly DA; Al-Sarireh B; Gwynne S; Ahmed I; Connolly K; Yim KL; Cunningham D; Armstrong T; Archer C; Roberts K; Ma YT; Springfeld C; Tjaden C; Hackert T; Büchler MW; Neoptolemos JP;
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):157-168. PubMed ID: 36521500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
    Sohal DPS; Duong M; Ahmad SA; Gandhi NS; Beg MS; Wang-Gillam A; Wade JL; Chiorean EG; Guthrie KA; Lowy AM; Philip PA; Hochster HS
    JAMA Oncol; 2021 Mar; 7(3):421-427. PubMed ID: 33475684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant
    Tempero MA; Pelzer U; O'Reilly EM; Winter J; Oh DY; Li CP; Tortora G; Chang HM; Lopez CD; Bekaii-Saab T; Ko AH; Santoro A; Park JO; Noel MS; Frassineti GL; Shan YS; Dean A; Riess H; Van Cutsem E; Berlin J; Philip P; Moore M; Goldstein D; Tabernero J; Li M; Ferrara S; Le Bruchec Y; Zhang G; Lu B; Biankin AV; Reni M;
    J Clin Oncol; 2023 Apr; 41(11):2007-2019. PubMed ID: 36521097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
    Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.
    Landry J; Catalano PJ; Staley C; Harris W; Hoffman J; Talamonti M; Xu N; Cooper H; Benson AB
    J Surg Oncol; 2010 Jun; 101(7):587-92. PubMed ID: 20461765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
    Sinn M; Bahra M; Liersch T; Gellert K; Messmann H; Bechstein W; Waldschmidt D; Jacobasch L; Wilhelm M; Rau BM; Grützmann R; Weinmann A; Maschmeyer G; Pelzer U; Stieler JM; Striefler JK; Ghadimi M; Bischoff S; Dörken B; Oettle H; Riess H
    J Clin Oncol; 2017 Oct; 35(29):3330-3337. PubMed ID: 28817370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
    Wang-Gillam A; Li CP; Bodoky G; Dean A; Shan YS; Jameson G; Macarulla T; Lee KH; Cunningham D; Blanc JF; Hubner RA; Chiu CF; Schwartsmann G; Siveke JT; Braiteh F; Moyo V; Belanger B; Dhindsa N; Bayever E; Von Hoff DD; Chen LT;
    Lancet; 2016 Feb; 387(10018):545-557. PubMed ID: 26615328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study.
    Philip PA; Sahai V; Bahary N; Mahipal A; Kasi A; Rocha Lima CMS; Alistar AT; Oberstein PE; Golan T; Metges JP; Lacy J; Fountzilas C; Lopez CD; Ducreux M; Hammel P; Salem M; Bajor D; Benson AB; Luther S; Pardee T; Van Cutsem E
    J Clin Oncol; 2024 Nov; 42(31):3692-3701. PubMed ID: 39088774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.